Summary
This observational metabolomics study of 333 cardiovascular events and matched controls identified shared and distinct plasma metabolite signatures associated with cardiovascular death, myocardial infarction, stroke, and heart failure in patients with coronary artery disease. Acylcarnitines predominated among shared biomarkers, whilst glycerophospholipid alterations were specific to heart failure. The findings suggest that incorporating metabolomic profiles into clinical risk assessment could improve prognostication of subsequent cardiovascular events.
UK applicability
The metabolomic signatures identified may have relevance for UK cardiovascular risk assessment and prevention strategies, though applicability would depend on validation in UK-based cohorts and integration with existing NHS risk prediction tools and clinical practice guidelines.
Key measures
Untargeted plasma metabolomics analysis; differential metabolites; cardiovascular event risk prediction; heart failure risk stratification
Outcomes reported
The study identified 23 shared differential metabolites associated with composite cardiovascular events, predominantly middle and long-chain acylcarnitines, and revealed distinct metabolic patterns for individual events including glycerophospholipid alterations specific to heart failure. Addition of metabolites to clinical markers significantly improved heart failure risk prediction.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.